Adenovir Pharma strengthens its patents for treatment of the serious and very contagious eye infection EKC

Adenovir Pharma’s patent applications relating to its novel ”Multivalent sialic acid derivates compound” (APD-514), for treatment of the serious and very contagious eye infection, epidemic keratoconjunctivitis (EKC), have been approved in several key markets: United States, Japan, EU and Australia.